Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High – Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $46.22 and last traded at $44.86, with a volume of 1685189 shares changing hands. The stock had previously closed at $39.12.

Analyst Ratings Changes

Several research firms recently weighed in on DNTH. Wedbush reiterated an “outperform” rating and set a $46.00 target price on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright upped their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $64.43.

Dianthus Therapeutics Stock Performance

The stock has a fifty day moving average price of $41.03 and a 200-day moving average price of $32.52. The firm has a market cap of $1.92 billion, a PE ratio of -12.89 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 216,538 shares of company stock worth $8,283,175 in the last 90 days. Company insiders own 16.56% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently modified their holdings of DNTH. Parkside Financial Bank & Trust boosted its holdings in Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Dianthus Therapeutics by 7.8% in the third quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock valued at $635,000 after purchasing an additional 1,170 shares during the period. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at $27,000. Finally, Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth $64,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.